Fig. 7: HM30-tesirine controls tumour growth and prolongs survival of mice bearing subcutaneous H460 tumours.

a Structure of the anti-xCT tesirine conjugate, HM30-tesirine. b Western blot using HM30-tesirine as the primary antibody in H1299 and H460 cell lysates. Actin was used as a loading control. c HM30-tesirine MTT dose-response in H460 and H1299 cells. d Axial [¹⁸F]FSPG PET/CT images from mice bearing H460 or H1299 tumours before initiation of treatment. The dashed circle indicates the tumour. Antitumour activity (e) and survival benefit (f) of control (saline treated), cisplatin treated and HM30-tesirine treated mice bearing subcutaneous H460 tumours. n = 5-6 mice per cohort. The arrows under the x-axis of (e) represent treatment cycles for cisplatin (green) and HM30-tesirine (red), with tumour volumes measured using electronic callipers. g IHC for Ki67 and cleaved caspase 3 from FFPE tumours taken at endpoint. Scale bar = 50 µm. Corresponding quantification of tissue staining for Ki67 (h) and cleaved caspase 3 (i). Data in (h, i) are presented as the mean values ± SD from n = 3 mice. For (c, h, i), comparisons were made using an unpaired two-tailed Student’s t-test. For (e) comparisons were made on day 8 using a one-way ANOVA with followed by t-tests multiple comparison correction (Tukey method). For (f), statistics were analysed with a log-rank (Mantel–Cox) test. To control the family-wise error rate in multiple comparisons, crude p values were adjusted by the Holm–Bonferroni method. For (b, c, e, f, h, i) source data are provided as a Source Data file.